News

Janssen enters deal with Genmab
Enlarge image

BusinessDenmarkUK

Janssen enters deal with Genmab

31.08.2012 - In a deal worth up to US$1.1bn Janssen Biotech Inc has licensed the human monoclonal antibody daratumumab from Danish Genmab A/S.

Janssen will pay US$55m up front to gain an exclusive worldwide license to develop and commercialise the patented fully human monoclonal antibody daratumumab and a backup CD38 antibody. On top of that, its parent Johnson & Johnson will invest additional US$80m in the Danish firm. After the issue of the new shares, the Horsham-based US company will own 10.7% of Genmab's share capital, the company said. The total potential agreement value including upfront payment, equity investment and milestones is in excess of US$1.1bn. Genmab could also be entitled to tiered double digit royalties. 

The human monoclonal antibody daratumumab targets the CD38 molecule which is highly expressed on the surface of multiple myeloma cells. The monoclonal antibody is currently in development for the rare cancer multiple myeloma  and may have potential in other cancer indications such as acute myeloid leukemia. 

“Much had been anticipated from a licensing deal for daratumumab and we believe this deal has more than met the expectation,” Nomura Code analyst Samir Devani said in a note to investors. The deal led Genmab cut its full-year operating loss forecast between US$24m and US$32m (DKK140m to DKK190m) from US$34m to US$42m (DKK200m to DKK250m) and to raise its guidance for 2012 revenue to US$73m to US$78m (DKK435m to DKK460m) from US$63m to US$67m (DKK375m to DKK400m).

It's the second deal with Janssen Biotech in this year. In July, Janssen had licensed Genmab's duobody technology.

http://www.european-biotechnology-news.com/news/news/2012-03/janssen-enters-deal-with-genmab.html

Stock marketsEU

29.01.2015 Denmark's Ascendis Pharma has successfully raised US$108m with its upsized NASDAQ IPO, while Irish animal health specialist Nexvet is waiting in the wings.

Contract ResearchEU

28.01.2015 EMA recommends suspending around 750 generic medicines marketed throughout the world after India’s GVK Biosciences is accused of faking bioequivalence studies. Meds considered critically important for patients will remain available.

RegulationEU

21.01.2015 The EMA is asking for comments on how to implement the transparency rules of EU Clinical Trial Regulation, pointing to the new clinical trial portal and database as the main instrument.

Stock marketsEUGermany

21.01.2015 2014 was a record year for biotech companies on the European stock market, with a total of €2.4bn raised in the year - 25% more than in the year before.

ResearchEUUK

20.01.2015 Ebola research projects are set to receive €215m in funding from the European Commission’s IMI2 Ebola+ programme. Among the project partners are vaccine developers Glaxosmithkline, Johnson&Johnson and Merck. 

Stock ExchangeUKDenmarkFrance

16.01.2015 It's time to get used to weekly IPO plans by European biotechs. UK's drug discovery firm Redx Pharma Ltd, established just five years ago, has come of age with their £80m (€105m) IPO plans.

M&ASwitzerland

14.01.2015 Pharma kingpin Roche has launched a billion-dollar transaction for a total of US$1.2bn (€1bn), taking over the majority of US cancer specialist Foundation Medicine.

PoliticsEU

14.01.2015 The European Parliament has backed the legislation allowing individual countries to restrict or prohibit the cultivation of genetically modified crops that have been authorised at EU level.

M&AIrelandUK

13.01.2015 Shire beefs up its rare disease portfolio after acquiring NPS Pharma with the aim of becoming a leading biotech in a US$5.2bn deal. Part of the deal is the US biotech's lead portfolio of gastrointestinal and hormone replacement therapies.

M&ASwitzerlandFrance

09.01.2015 The excitement surrounding CRISPR genome editing shows no sign of abating. This month, Novartis and US biotech Intellia Therapeutics became the first ever biotech-pharma collaboration to use the groundbreaking technology.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CYTOS0.36 CHF9.09%
  • FORMYCON15.48 EUR8.25%
  • MAGFORCE5.18 EUR3.39%

FLOP

  • BB BIOTECH244.15 EUR-4.91%
  • CO.DON2.34 EUR-2.50%
  • MORPHOSYS76.24 EUR-1.78%

TOP

  • CYTOS0.36 CHF56.5%
  • FORMYCON15.48 EUR53.6%
  • ADDEX3.28 CHF41.4%

FLOP

  • BIOFRONTERA1.93 EUR-16.1%
  • ACTELION100.80 CHF-13.3%
  • MOLOGEN5.75 EUR-9.4%

TOP

  • SANTHERA105.00 CHF2558.2%
  • WILEX1.96 EUR168.5%
  • FORMYCON15.48 EUR103.7%

FLOP

  • CYTOS0.36 CHF-90.0%
  • 4SC0.84 EUR-49.7%
  • MOLOGEN5.75 EUR-49.7%

No liability assumed, Date: 29.01.2015